EP3954684A1 - Verfahren zur herstellung von hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen - Google Patents

Verfahren zur herstellung von hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen Download PDF

Info

Publication number
EP3954684A1
EP3954684A1 EP21181833.1A EP21181833A EP3954684A1 EP 3954684 A1 EP3954684 A1 EP 3954684A1 EP 21181833 A EP21181833 A EP 21181833A EP 3954684 A1 EP3954684 A1 EP 3954684A1
Authority
EP
European Patent Office
Prior art keywords
azabicyclo
heptan
cyclopropyl
methoxy
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21181833.1A
Other languages
English (en)
French (fr)
Inventor
Jianhua Chao
Rakesh Jain
Lily HU
Jason Gustaf Lewis
Helene Baribault
Jeremy Caldwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardelyx Inc
Original Assignee
Ardelyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardelyx Inc filed Critical Ardelyx Inc
Publication of EP3954684A1 publication Critical patent/EP3954684A1/de
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Definitions

  • the present invention is directed to modulators of a nuclear hormone receptor, famesoid X receptor (FXR), useful in the treatment of diseases or disorders associated with FXR proteins.
  • FXR famesoid X receptor
  • the invention is related to compounds and compositions which modulate FXR, methods of treating diseases or disorders associated with FXR, and methods of synthesis of these compounds.
  • FXR is a ligand-activated transcription factor. Upon binding of a ligand, FXR either binds to DNA at the FXR response elements (FXREs) as a monomer, or forms a heterodimer with retinoid X receptor (RXR) and then binds to FXREs, regulating the transcription of a variety of target genes.
  • FXREs FXR response elements
  • RXR retinoid X receptor
  • FXR target genes that are involved in a wide range of physiological functions including bile acid homeostasis (i.e., BACS, BAAT, BSEP, FGF15/19, etc.), cholesterol and lipoprotein metabolism (i.e., Apolipoprotein C-I, II, IV, Apolipoprotein E, MDR3, Human complement C3, ApoA-1, hepatic lipase, SREPB-1c), glucose metabolism ( i.e., PEPCK, GSK3, AKR1B7, GLUT4, G6Pase), and xenobiotics metabolism ( i.e., GST ⁇ 3, GST ⁇ 4, GST ⁇ 1, GST ⁇ 3, SULT1A1, SULT1A2).
  • BACS bile acid homeostasis
  • BAAT i.e., BAAT, BSEP, FGF15/19, etc.
  • cholesterol and lipoprotein metabolism i.e., Apolipoprotein C-I, II, IV, Apolipoprotein E, M
  • FXR a regulator of cellular inflammatory and immune responses.
  • Activation of FXR can provide anti-inflammatory effects by negative regulation of nuclear factor ⁇ B (NF ⁇ B) pathway, reducing the expression of NF ⁇ B and the many pro-inflammatory cytokines associated with this pathway
  • NF ⁇ B nuclear factor ⁇ B
  • Moschetta, A. “Deciphering the nuclear bile acid receptor FXR paradigm, " Nucl. Recept. Signal., 2010, 8, e005 ; Huang, W., et al., "FXR: a metabolic regulator and cell protector," Cell Res., 2008, 1087-1095 ).
  • FXR plays a key role in the synthesis, transport and metabolism of bile acids (BAs) and the many physiological and pathophysiological conditions that involve BAs.
  • BAs bile acids
  • activation of FXR has been shown to lead to the increased expression of short heterodimer partner (SHP), which in turn inactivates liver receptor homolog-1 (LRH-1) and inhibits the cholesterol 7- alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in the first step of biosynthesis of primary bile acids from cholesterol, thereby reduces the production of bile acids.
  • SHP short heterodimer partner
  • LH-1 liver receptor homolog-1
  • CYP7A1 cholesterol 7- alpha-hydroxylase
  • FXR farnesoid Activation of FXR in the liver has also been shown to downregulate transporters like Na-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting peptides (OATPs) preventing the uptake of bile acids to liver.
  • NTCP Na-taurocholate co-transporting polypeptide
  • OATPs organic anion-transporting peptides
  • FXR has also been shown to play an important role in the inflammation control of various liver and intestinal diseases ( Shaik, F. B., et al., "Role of farnesoid X receptor in inflammation and resolution," Inflamm. Res. 2015, 64, 9-20 ). Activation of FXR has been shown to repress the NF ⁇ B pathway, a prototypical proinflammatory signaling pathway, and inhibit the expression of key cytokines such as TNF ⁇ , IL-1 ⁇ , and IL-6.
  • proinflammatory cytokines e.g., TNF ⁇ , IL-1 ⁇ , IFN ⁇
  • profibrotic genes i.e., Collagen ⁇ 1, TIMP-1, and ⁇ SMA
  • Activation of FXR with FXR activators in the TNBS induced murine inflammatory bowel disease model has been shown to inhibit the above cytokines and provide protection against inflammation and fibrosis, subsequently against the development of colitis ( Vavassori, P., "The bile acid receptor FXR is a modulator of intestinal innate immunity," J. Immunol. 2009, 183, 6251-6261 ).
  • FXR activators has the potential to be a treatment for a range of diseases including bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, hepatic and colon cancers, and other disorders.
  • PBC primary biliary cirrhosis
  • NASH nonalcoholic steatohepatitis
  • known FXR activators have demonstrated toxicities, treatment limiting adverse effects, and other issues. For these reasons, there remains a need for novel and potent small molecule FXR activators.
  • Another aspect of the invention relates to a method of treating a disease or disorder in which FXR plays a role.
  • the method comprises administering to a patient in need of a treatment for diseases or disorders in which FXR plays a role an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention is directed to a method of modulating FXR.
  • the method involves administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention is directed to a method of activating FXR.
  • the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of treating a liver disease.
  • the method comprises administering to a patient in need of a treatment for a liver disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of treating an intestinal disease.
  • the method comprises administering to a patient in need of a treatment for an intestinal disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of treating a kidney disease.
  • the method comprises administering to a patient in need of a treatment for a kidney disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of treating an autoimmune disorder.
  • the method comprises administering to a patient in need of a treatment for an autoimmune disorder an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of treating cancer.
  • the method comprises administering to a patient in need of a treatment for cancer an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof
  • compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease associated with activating FXR.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease in which FXR plays a role.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a liver disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating an intestinal disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a kidney disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating an autoimmune disorder.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating cancer.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease associated with activating FXR.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease in which FXR plays a role.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a liver disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of an intestinal disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a kidney disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of an autoimmune disorder.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of cancer.
  • the present invention further provides methods of treating a disease or disorder associated with modulation of FXR including, but not limited to, liver diseases, intestinal diseases, kidney disease, autoimmune disorders, or cancer, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • a disease or disorder associated with modulation of FXR including, but not limited to, liver diseases, intestinal diseases, kidney disease, autoimmune disorders, or cancer, comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention provides activators of FXR that are therapeutic agents in the treatment of diseases, such as liver diseases, intestinal diseases, kidney disease, autoimmune disorders, and cancer.
  • diseases such as liver diseases, intestinal diseases, kidney disease, autoimmune disorders, and cancer.
  • the present invention provides the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with the modulation of FXR.
  • the present invention relates to compounds and compositions that are capable of modulating the activity of FXR.
  • the invention features methods of treating, preventing or ameliorating a disease or disorder in which FXR plays a role by administering to a patient in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the methods of the present invention can be used in the treatment of a variety of FXR dependent diseases and disorders by increasing the activity of nuclear receptor FXR.
  • Activation or modulation of FXR provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, liver diseases, intestinal diseases, kidney diseases, autoimmune disorders, and cancer.
  • the compounds of Formula (I) are described: and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof, wherein Li, A, X 1 , X 2 , R 1 , R 2 , and R 3 are as described herein.
  • an element means one element or more than one element.
  • an alkyl group that is optionally substituted can be a fully saturated alkyl chain (e.g., a pure hydrocarbon).
  • the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein.
  • optionally substituted means that a given chemical moiety has the potential to contain other functional groups, but does not necessarily have any further functional groups.
  • Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH 2 CN, -O-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkenyl, (C 1 -C 6 ) alkynyl, (C 1 -C 6 ) hydroxyalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 )haloalkoxy, (C 3 -C 7 ) cycloalkyl, aryl, heterocycloalkyl, heteroaryl, -O-(C 2 -C 6 ) alkenyl, -O-(C 2 -C 6 ) alkynyl, (C 2 -C 6 ) alkenyl, (C 2 -C
  • substituted means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions.
  • an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
  • aryl refers to cyclic, aromatic hydrocarbon groups that have 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl or naphthyl. Where containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group may be joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl).
  • the aryl group may be optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment.
  • substituents include, but are not limited to, -H, -halogen, -O-(C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkyl, -O-(C 2 -C 6 ) alkenyl, -O-(C 2 -C 6 ) alkynyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, -OH, -OP(O)(OH) 2 , -OC(O)(C 1 -C 6 ) alkyl,-C(O)(C 1 -C 6 ) alkyl, -OC(O)O(C 1 -C 6 ) alkyl, -NH 2 , NH((C 1 -C 6 ) alkyl), N((C 1 -C 6 ) alkyl) 2 ,-S(O) 2 -(C 1 -C 6 ) alkyl, -S
  • an aryl group herein defined may be fused to an unsaturated or partially saturated ring, or fused with a fully saturated ring.
  • exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.
  • heteroaryl means a monovalent monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical, containing one or more ring heteroatoms selected from the group consisting of N, O, and S, the remaining ring atoms being C.
  • Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from the group consisting of N, O, and S.
  • the aromatic radical is optionally substituted independently with one or more substituents described herein.
  • Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridin
  • heteroaryl groups herein defined may be fused to an unsaturated or partially saturated ring containing a heteroatom selected from N, O and S; or fused with a fully saturated ring containing a heteroatom selected from N, O and S.
  • Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-1H--isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
  • Halogen or "halo" refers to fluorine, chlorine, bromine, or iodine.
  • Alkyl either alone or in combination with other groups (e.g. alkoxy, haloalkyl and the like) refers to a straight or branched chain saturated, unsaturated (fully or partially) hydrocarbon containing 1-12 carbon atoms.
  • Examples of a (C 1 -C 6 ) alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert -butyl, isopentyl, neopentyl, and isohexyl.
  • "alkyl" is fully saturated.
  • Alkoxy refers to a straight or branched chain saturated or unsaturated (fully or partially) hydrocarbon containing 1-12 carbon atoms containing a terminal "O" in the chain, e.g., -O(alkyl).
  • alkoxy groups include without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups. In an embodiment, "alkoxy" is fully saturated.
  • Alkoxyalkoxy refers to an alkoxy group as defined herein which is substituted with an alkoxy group e.g., -O(alkyl)-O-(alkyl).
  • alkoxyalkoxy groups include without limitation, methoxymethoxy, ethoxyethoxy, propoxymethoxy, or ethoxymethoxy.
  • Alkenyl refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms.
  • the "alkenyl” group contains at least one double bond in the chain.
  • the double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group.
  • alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl.
  • An alkenyl group can be unsubstituted or substituted.
  • Alkenyl, as herein defined may be straight or branched.
  • Alkynyl refers to a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms.
  • the "alkynyl” group contains at least one triple bond in the chain. Examples of alkynyl groups include ethynyl, propanyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl.
  • An alkynyl group can be unsubstituted or substituted.
  • Cycloalkyl or “carbocyclyl” means monocyclic or polycyclic saturated or unsaturated (fully or partially) non-aromatic carbon rings containing 3-18 carbon atoms.
  • Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof.
  • a C 3 -C 8 cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms.
  • a cycloalkyl group can be fused (e.g., decalin) or bridged (e.g., norbornane). In an embodiment, "cycloalkyl" is fully saturated.
  • Heterocyclyl or “heterocycloalkyl” monocyclic or polycyclic rings containing carbon and heteroatoms taken from oxygen, nitrogen, or sulfur and wherein there is not delocalized ⁇ electrons (aromaticity) shared among the ring carbon or heteroatoms.
  • heterocycloalkyl comprises one or two 4- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl.
  • the heterocycloalkyl ring structure may be substituted by one or more substituents.
  • heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, and homotropanyl.
  • "heterocycle” or “heterocycloalkyl” is fully saturated.
  • hydroxyalkyl means an alkyl group as defined above, where the alkyl group is substituted with one or more -OH groups.
  • hydroxy alkyl groups include HO-CH 2 -, HO-CH 2 -CH 2 - and CH 3 -CH(OH)-.
  • "hydroxyalkyl" is fully saturated.
  • haloalkyl refers to an alkyl group, as defined herein, which is substituted one or more halogen.
  • haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc. In an embodiment, "haloalkyl" is fully saturated.
  • haloalkoxy refers to an alkoxy group, as defined herein, which is substituted one or more halogen.
  • haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc. In an embodiment, "haloalkoxy" is fully saturated.
  • cyano as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, e.g., C ⁇ N.
  • Spirocycloalkyl or “spirocyclyl” means carbogenic bicyclic ring systems with both rings connected through a single atom.
  • the ring can be different in size and nature, or identical in size and nature. Examples include spiropentane, spriohexane, spiroheptane, spirooctane, spirononane, or spirodecane.
  • One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
  • One or more of the carbon atoms in the spirocycle can be substituted with a heteroatom (e.g ., O, N, S, or P).
  • a (C 3 -C 12 ) spirocycloalkyl is a spirocycle containing between 3 and 12 carbon atoms.
  • One or more of the carbon atoms can be substituted with a heteroatom
  • "spirocycloalkyl" or “spirocyclyl” is fully saturated.
  • spiroheterocycloalkyl or “spiroheterocyclyl” is understood to mean a spirocycle wherein at least one of the rings is a heterocycle (e.g., at least one of the rings is furanyl, morpholinyl, or piperadinyl). In an embodiment, “spiroheterocycloalkyl” or “spiroheterocyclyl is fully saturated.
  • GW4064 is an FXR agonist compound having the following structure.
  • solvate refers to a complex of variable stoichiometry formed by a solute and solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, MeOH, EtOH, and AcOH. Solvates wherein water is the solvent molecule are typically referred to as hydrates. Hydrates include compositions containing stoichiometric amounts of water, as well as compositions containing variable amounts of water.
  • the term "isomer” refers to compounds that have the same composition and molecular weight but differ in physical and/or chemical properties. The structural difference may be in constitution (geometric isomers) or in the ability to rotate the plane of polarized light (stereoisomers). With regard to stereoisomers, the compounds of Formula (I) may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers.
  • compositions comprising an effective amount of a disclosed compound and a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable salts include, e.g., water-soluble and water-insoluble salts, such as the acetate, amsonate (4,4-diaminostilbene-2,2-disulfonate), benzenesulfonate, benzonate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium, calcium edetate, camsylate, carbonate, chloride, citrate, clavulariate, dihydrochloride, edetate, edisylate, estolate, esylate, fumerate, fiunarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexafluorophosphate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphtho
  • a "patient” or “subject” is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or non-human primate, such as a monkey, chimpanzee, baboon or rhesus.
  • an "effective amount" when used in connection with a compound is an amount effective for treating or preventing a disease in a subject as described herein.
  • carrier encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.
  • treating refers to improving at least one symptom of the subject's disorder. Treating includes curing, improving, or at least partially ameliorating the disorder.
  • disorder is used herein to mean, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
  • administer refers to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject's body.
  • prodrug means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound.
  • autoimmune disease includes, but is not limited to, the following autoimmune diseases: Amyotrophic Lateral Sclerosis (ALS), Autoimmune Atherosclerosis, Autoimmune Diabetes Insipidus, Autoimmune Gastritis, Autoimmune Hepatitis, Autoimmune Interstitial Cystitis, Autoimmune Uveitis, Autoimmune Vasculitis, Behcet's Disease, Celiac Disease, Chronic Fatigue Syndrome, Crohn's Disease, chronic active hepatitis, Diabetes Mellitus, Multiple Sclerosis, PBC, Primary Biliary Cirrhosis, Primary Glomerulonephritis, Primary Sclerosing Cholangitis, Psoriasis, Psoriatic Arthritis, Scleroderma, Sjogren's Syndrome, Systemic Lupus Erythematosus, Ulcerative Colitis, and Vasculitis.
  • ALS Amyotrophic Lateral Sclerosis
  • Atherosclerosis Autoimmune Atherosclerosis
  • kidney disease includes, but is not limited to the following kidney diseases: fibrotic renal disease and diabetic nephrophathy.
  • liver disease includes, but is not limited to, the following liver diseases: primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, intra- and extra-cholestasis, portal vein hypertension (PAH), obesity and Type 2 Diabetes.
  • PBC primary biliary cirrhosis
  • PSC primary sclerosing cholangitis
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • alcoholic liver disease intra- and extra-cholestasis
  • PAH portal vein hypertension
  • obesity Type 2 Diabetes
  • intestinal disease includes, but is not limited to the following intestinal diseases: inflammatory bowel disease, Crohn's disease, ulcerative colitis, proctitis, pouchitis, Celiac's disease and bile acid diarrhea.
  • cancer includes, but is not limited to, the following cancers: hepatocellular carcinoma, hepatocellular adenoma, cholangiocarcinoma, colorectal cancer, colorectal adenoma, ileal adenoma, renal cancer, oesophageal cancer, gastric cancer, gastric carcinoma, colon carcinoma, gastrointestinal stromal carcinoma, bile duct carcinoma, renal carcinoma, breast cancer, and Barett's esophagus, and combinations thereof.
  • the present invention relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of activating FXR, which are useful for the treatment of diseases and disorders associated with modulation of a FXR protein or receptor.
  • the invention further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for activating FXR.
  • the present invention relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of activating FXR, which are useful for the treatment of diseases and disorders associated with modulation of a FXR protein.
  • the invention further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for activating FXR.
  • compounds of the invention have the structure of Formula (I): or a salt thereof, wherein:
  • compounds of the invention have the Formula (I) wherein:
  • the compounds of Formula (I) have the structure of Formula (Ia) or (Ib): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Ic) or (Id): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Ie) or (If): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Ig) or (Ih): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Ii) or (Ij): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Ik) or (Il): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Im) or (In): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Io) or (Ip): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Iq) or (Ir): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Is) or (It): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Iu) or (Iv): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Iw) or (Ix): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Iy) or (Iz): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • the compounds of Formula (I) have the structure of Formula (Iaa) or (Ibb): and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
  • X 1 is CHR y or C(O) and X 2 is NR x or N + (O - )R x .
  • X 1 is CHR y and X 2 is NR x or N + (O - )R x .
  • X 1 is C(O) and X 2 is NR x or N + (O - )R x .
  • X 1 is CHR y and X 2 is NR x .
  • X 1 is C(O) and X 2 is NR x .
  • X 1 is CHR y and X 2 is N + (O - )R x .
  • X 1 is C(O) and X 2 is N + (O - )R x .
  • X 1 is CH 2 and X 2 is NR x .
  • X 1 is NR x or N + (O - )R x and X 2 is CHR y or C(O).
  • X 1 is NR x and X 2 is CHR y or C(O).
  • X 1 is N + (O - )R x and X 2 is CHR y or C(O).
  • X 1 is NR x and X 2 is CHR y .
  • X 1 is NR x and X 2 is C(O).
  • X 1 is N + (O - )R x and X 2 is CHR y . In another embodiment, X 1 is N + (O - )R x and X 2 is C(O). In another embodiment, X 1 is NR x and X2 is CH2.
  • L 2 is a bond. In another embodiment L 2 is-S(O) 2 -.
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 .
  • A is (C 3 -C 8 ) cycloalkyl.
  • A is (C 3 -C 8 ) cycloalkyl substituted with one or more R 7 .
  • A is (C 6 -C 10 ) aryl.
  • A is (C 6 -C 10 ) aryl substituted with one or more R 7 .
  • A is phenyl optionally substituted with one or more R 7 .
  • A is phenyl unsubstituted by R 7 while R 1 and R 2 are both a halogen. In another embodiment, A is phenyl unsubstituted by R 7 while R 1 and R 2 are both a Cl at the ortho positions relative to the isoxazole ring.
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 . In another embodiment, A is heterocycloalkyl comprising one or two 5-to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, substituted with one or more R 7 .
  • A is heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 .
  • A is heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, substituted with one or more R 7 .
  • A is (C 3 -C 8 ) cycloalkyl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl or heterocycloalkyl are optionally substituted with one or more R 7 .
  • A is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the aryl or heteroaryl is optionally substituted with one or more R 7 .
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7 .
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl, wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 .
  • A is (C 6 -C 10 ) aryl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the aryl or heterocycloalkyl are optionally substituted with one or more R 7 .
  • B is (C 6 -C 10 ) aryl optionally substituted with one or more R 5 .
  • B is heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 5 .
  • B is (C 6 -C 10 ) aryl.
  • B is (C 6 -C 10 ) aryl substituted with one or more R 5 .
  • B is heteroaryl.
  • B is heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, substituted with one or more R 5 .
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl are substituted with one or more R 5 .
  • R 1 is H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 1 is halogen, CN, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 1 is H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 1 is H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 1 is (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 1 is H, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 1 is (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 1 is H, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or halogen. In yet another embodiment, R 1 is (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or halogen. In another embodiment, R 1 is H, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen. In yet another embodiment, R 1 is (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 1 is (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 1 is H, (C 1 -C 6 ) haloalkyl, or halogen.
  • R 1 is (C 1 -C 6 ) haloalkyl or halogen.
  • R 2 is H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 2 is halogen, CN, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 2 is H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 2 is H, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 2 is (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 2 is H, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 2 is (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 2 is H, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or halogen. In yet another embodiment, R 2 is (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or halogen. In another embodiment, R 2 is H, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen. In yet another embodiment, R 2 is (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, or halogen.
  • R 2 is (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, halogen, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more R 9 .
  • R 2 is H, (C 1 -C 6 ) haloalkyl, or halogen.
  • R 2 is (C 1 -C 6 ) haloalkyl or halogen.
  • R 1 and R 2 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl ring.
  • R 1 and R 2 together when attached to the same carbon atom form a (C 3 -C 8 ) spirocycloalkyl ring substituted with one to three R 8 .
  • R 1 and R 2 together when attached to the same atom form a (C 3 -C 8 ) spiroheterocycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 together when attached to the same atom form a (C 3 -C 8 ) spiroheterocycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 together when attached to the same atom form a (C 3 -C 8 ) spiroheterocycloalkyl ring.
  • R 1 and R 2 together when attached to the same atom form a (C 3 -C 8 ) spiroheterocycloalkyl ring substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 ) cycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 ) cycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 ) cycloalkyl ring.
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a (C 3 -C 8 ) cycloalkyl ring substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring.
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heterocycloalkyl ring substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form an aryl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form an aryl ring.
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form an aryl ring substituted with one to three R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 on adj acent atoms together with the atoms to which they are attached form a heteroaryl ring.
  • R 1 and R 2 on adjacent atoms together with the atoms to which they are attached form a heteroaryl ring substituted with one to three R 8 .
  • R 1 and R 2 together with the atoms to which they are attached form a (C 4 -C 8 ) cycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 together with the atoms to which they are attached form a (C 4 -C 8 ) cycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 together with the atoms to which they are attached form a (C 4 -C 8 ) cycloalkyl ring.
  • R 1 and R 2 together with the atoms to which they are attached form a (C 4 -C 8 ) cycloalkyl ring substituted with one to three R 8 .
  • R 1 and R 2 when cycloalkyl or heterocycloalkyl, R 1 and R 2 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one or more R 8 .
  • R 1 and R 2 when cycloalkyl or heterocycloalkyl, R 1 and R 2 together with the atoms to which they are attached form a heterocycloalkyl ring optionally substituted with one to three R 8 .
  • R 1 and R 2 when cycloalkyl or heterocycloalkyl, R 1 and R 2 together with the atoms to which they are attached form a heterocycloalkyl ring.
  • R 1 and R 2 when cycloalkyl or heterocycloalkyl, R 1 and R 2 together with the atoms to which they are attached form a heterocycloalkyl ring substituted with one to three R 8 .
  • R 3 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, (C 1 -C 4 ) hydroxyalkyl, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 3 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, or. (C 1 -C 4 ) alkoxy.
  • R 3 is (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or (C 1 -C 4 ) hydroxyalkyl.
  • R 3 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, (C 1 -C 4 ) hydroxyalkyl, or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 3 is (C 1 -C 4 ) alkyl or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 3 is (C 1 -C 4 ) alkyl or (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen and (C 1 -C 6 ) alkyl.
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 6 ) alkyl.
  • R 4 is COOR 6a , -(CH 2 ) n -COOR 6a , CONR 6b OH, CONR 6b R 6c , CONH(CH 2 ) n COOR 6a , CONH(CH 2 ) n R 6a , -(CH 2 ) n CONH(CH 2 ) n R 6a , CONR 6b SO 2 R 6d , CONR 6b SO 2 (CH 2 ) n R 6d , -(CH 2 ) n -CONR 6b SO 2 R 6d , CONR 6b SO 2 (CH 2 ) n N(CO)R 6d CONH(CH 2 ) n SO 2 R 6e , COR 6f
  • R 4 is COOR 6a . In an embodiment, R 4 is -alkyl-COOR 6a . In another embodiment, R 4 is -(CH 2 ) n -COOR 6a . In an embodiment, R 4 is CONR 6b OH. In another embodiment, R 4 is CONR 6b R 6c . In yet another embodiment, R 4 is CONH(CH 2 ) n COOR 6a . In another embodiment, R 4 is CONH(CH 2 ) n SO 2 R 6e . In yet another embodiment, R 4 is CONH(CH 2 ) n COOR 6a , CONH(CH 2 ) n R 6a , -(CH 2 ) n CONH(CH 2 ) n R 6a .
  • R 4 is CONH(CH 2 ) n R 6a . In yet another embodiment, R 4 is -(CH 2 ) n CONH(CH 2 ) n R 6a . In yet another embodiment, R 4 is CONR 6b SO 2 R 6d . In yet another embodiment, R 4 is -(CH 2 ) n -NR 6b C(O)R 6c . In yet another embodiment, R 4 is -(CH 2 ) n -N(OH)-C(O)R 6c . In yet another embodiment, R 4 is - alkyl-CONR 6b SO 2 R 6d . In yet another embodiment, R 4 is COR 6f , (CH 2 ) n PO(OR 6g ) 2 .
  • R 4 is COO(CH 2 ) n PO(OR 6g ) 2 . In yet another embodiment, R 4 is SO 2 NR 6b (CH 2 ) n COOR 6a . In yet another embodiment, R 4 is SO 2 R 6e . In yet another embodiment, R 4 is oxo.
  • R 4 is (C 3 -C 8 ) cycloalkyl optionally substituted with (CH 2 ) n COOR 6a , COOR 6a , CONR 6b OH, CONR 6b R 6c , CONH(CH 2 ) n COOR 6a , CONR 6b SO 2 R 6d , CONH(CH 2 ) n SO 2 R 6e , COR 6f , (CH 2 ) n PO(OR 6g ) 2 , COO(CH 2 ) n PO(OR 6g ) 2 , SO 2 NR 6b (CH 2 ) n COOR 6a , SO 2 R 6c .
  • R 4 is heterocycloalkyl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S; and said heterocycloalkyl is optionally substituted with (CH 2 ) n COOR 6a , COOR 6a , CONR 6b OH, CONR 6b R 6c , CONH(CH 2 ) n COOR 6a , CONR 6b SO 2 R 6d , CONH(CH 2 ) n SO 2 R 6e , COR 6f , (CH 2 ) n PO(OR 6g ) 2 , COO(CH 2 ) n PO(OR 6g ) 2 , SO 2 NR 6b (CH 2 ) n COOR 6a , SO 2 R 6e .
  • R 4 is or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S; and said said heteraryl is optionally substituted with (CH 2 ) n COOR 6a , COOR 6a , CONR 6b OH, CONR 6b R 6c , CONH(CH 2 ) n COOR 6a , CONR 6b SO 2 R 6d , CONH(CH 2 ) n SO 2 R 6e , COR 6f , (CH 2 ) n PO(OR 6g ) 2 , COO(CH 2 ) n PO(OR 6g ) 2 , SO 2 NR 6b (CH 2 ) n COOR 6b , SO 2 R 6 .
  • R 4 is COOR 6a , CONR 6b SO 2 R 6d , or CONR 6b R 6c . In yet another embodiment, R 4 is COOR 6a , CONR 6b SO 2 R 6d , or CONH(CH 2 ) n SO 2 R 6e . In another embodiment, R 4 is COOR 6a , CONR 6b SO 2 R 6d , or CONH(CH 2 ) n COOR 6a . In yet another embodiment, R 4 is COOR 6a , CONR 6b SO 2 R 6d , or heterocycloalkyl comprising one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • R 4 is COOR 6a , CONR 6b SO 2 R 6d , CONR 6b R 6c , or heterocycloalkyl comprising one 5- to 7-membered ring and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • R 4 is COOR 6a , CONR 6b SO 2 R 6d , or heterocycloalkyl comprising one 5- to 7-membered ring and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • R 4 is CONH(CH 2 ) n COOR 6a or CONH(CH 2 ) n SO 2 R 6e .
  • R 4 is CONR 6b R 6c or CONH(CH 2 ) n COOR 6a . In another embodiment, R 4 is CONR 6b SO 2 R 6d or CONH(CH 2 ) n SO 2 R 6e .
  • n is 1. In another embodiment, n is 2. In another embodiment, n is 3. In another embodiment, n is 4.
  • R 5 is halogen, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, CN, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl,
  • R 5 is halogen, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, or (C 3 -C 8 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, and (C 1 -C 6 ) haloalkoxy.
  • R 5 is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, and (C 1 -C 6 ) haloalkoxy.
  • the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected
  • R 5 is halogen, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, or (C 3 -C 8 ) cycloalkyl.
  • R 5 is halogen, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkoxy, or (C 1 -C 4 ) haloalkoxy.
  • R y is H, (C 1 -C 6 ) alkyl, (C 2 -C 6 ) alkenyl, (C 2 -C 6 ) alkynyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) haloalkoxy or halogen.
  • R y is H.
  • R y is methyl.
  • R y is ethyl.
  • R y is CF 3.
  • R y is (C 1 -C 6 ) alkyl.
  • R y is (C 1 -C 6 ) haloalkyl.
  • R y is alkoxyalkyl.
  • R 6a is H, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl
  • R 6a is H, (C 1 -C 4 ) alkyl, or (C 1 -C 4 ) haloalkyl.
  • R 6a is H, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and ⁇ OH.
  • R 6a is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6a is H or (C 1 -C 4 )
  • R 6b is H, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy
  • R 6b is H, (C 1 -C 4 ) alkyl, or (C 1 -C 4 ) haloalkyl.
  • R 6b is H, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6b is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6b is H or (C 1 -C 4 )
  • R 6c is H, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy
  • R 6c is H, (C 1 -C 4 ) alkyl, or (C 1 -C 4 ) haloalkyl.
  • R 6c is H, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is H or (C 1 -C 4 )
  • R 6d is (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, COOH, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) al
  • R 6d is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6
  • R 6d is (C 1 -C 4 ) alkyl, or (C 1 -C 4 ) haloalkyl.
  • R 6d is (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6d is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • the heterocycloalkyl comprises one or two 5- to 7-membered rings and
  • R 6d is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl, wherein the alkyl or cycloalkyl are optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6d is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl, wherein the alkyl or cycloalkyl are optionally substituted with one or more -OH. In another embodiment, R 6d is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl.
  • R 6c is -OH, (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the alkyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) al
  • R 6c is -OH, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) alkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • the heterocycloalkyl comprises one or two 5- to 7-membered rings and
  • R 6e is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6e is (C 6 -C 10 ) aryl optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6e is heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6e is (C 3 -C 8 ) cycloalkyl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl or heterocycloalkyl are optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6e is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the aryl or heteroaryl is optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl, wherein the alkyl or cycloalkyl are optionally substituted with one or more substituents each independently selected from the group consisting of halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) haloalkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, and -OH.
  • R 6c is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl, wherein the alkyl or cycloalkyl are optionally substituted with one or more ⁇ OH.
  • R 6e is (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl.
  • R 6c is -OH, (C 1 -C 4 ) alkyl or (C 3 -C 8 ) cycloalkyl.
  • R 6f is (C 1 -C 6 ) alkyl or (C 1 -C 6 ) haloalkyl. In another embodiment, R 6f is (C 1 -C 6 ) alkyl. In another embodiment, R 6f is methyl. In another embodiment, R 6f is (C 1 -C 6 ) haloalkyl. In another embodiment, R 6f trifluoromethyl.
  • R 6g is H or (C 1 -C 6 ) alkyl optionally substituted with -O-CO-(C 1 -C 6 ) alkyl. In an embodiment, R 6g is H. In an embodiment, R 6g is (C 1 -C 6 ) alkyl optionally substituted with -O-CO-(C 1 -C 6 ) alkyl. In an embodiment, R 6g is -CH 2 -O-C(O)-C(CH 3 ) 3 .
  • R 7 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or CN.
  • R 7 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or CN.
  • R 7 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • R 7 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, or (C 1 -C 4 ) alkoxy.
  • R 7 is (C 1 -C 4 ) alkyl, (C 2 -C 4 ) alkenyl, (C 2 -C 4 ) alkynyl, (C 1 -C 4 ) alkoxy, or halogen. In another embodiment, R 7 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or halogen.
  • R 7 is (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or halogen. In another embodiment, R 7 is (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or halogen.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or halogen.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • R 8 is (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halogen, or -OH.
  • R 8 is halogen, or -OH.
  • R 8 is (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, or ⁇ OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, halogen, or ⁇ OH.
  • R 8 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or halogen.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • R 9 is (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, halogen, or -OH.
  • R 9 is halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy, halogen, or -OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, halogen, or ⁇ OH.
  • R 9 is (C 1 -C 4 ) alkyl, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, (C 1 -C 4 ) haloalkoxy, or -OH.
  • m is 0. In another embodiment, m is 1. In another embodiment, m is 2. In another embodiment, m is 1 or 2. In another embodiment, m is 0 or 1.
  • p is 1. In another embodiment, p is 2.
  • A is (C 6 -C 10 ) aryl, (C 3 -C 8 ) cycloalkyl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is (C 6 -C 10 ) aryl or (C 3 -C 8 ) cycloalkyl.
  • A is (C 6 -C 10 ) aryl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is (C 3 -C 8 ) cycloalkyl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is phenyl or (C 3 -C 8 ) cycloalkyl.
  • A is phenyl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • A is phenyl.
  • A is cyclohexyl, bicyclo[2.2.2.]octanyl, or spiro[2.5]octanyl. In yet another embodiment, A is cyclohexyl or bicyclo[2.2.2.]octanyl. In another embodiment, A is bicyclo[2.2.2.]octanyl, or spiro[2.5]octanyl. In yet another embodiment, A is cyclohexyl, bicyclo[2.2.2.]octanyl, or tetrahydropyranyl. In another embodiment, A is cyclohexyl. In yet another embodiment, A is bicyclo[2.2.2.]octanyl. In another embodiment, A is tetrahydropyranyl.
  • R 1 and R 2 are each independently H, halogen, (C 1 -C 6 ) alkoxy, or (C 1 -C 6 ) haloalkoxy.
  • R 1 and R 2 are each independently H, halogen, or (C 1 -C 6 ) haloalkyl.
  • R 1 and R 2 are each independently halogen or (C 1 -C 6 ) haloalkyl.
  • R 1 is H and R 2 is halogen, (C 1 -C 6 ) haloalkyl, or (C 1 -C 6 ) haloalkoxy.
  • R 1 is H and R 2 is (C 1 -C 6 ) haloalkyl or (C 1 -C 6 ) haloalkoxy. In another embodiment, R 1 is H and R 2 is (C 1 -C 6 ) haloalkyl. In yet another embodiment, R 1 is H and R 2 is (C 1 -C 6 ) haloalkoxy. In another embodiment, R 1 is halogen and R 2 is halogen, (C 1 -C 6 ) haloalkyl, or (C 1 -C 6 ) haloalkoxy. In yet another embodiment, R 1 is halogen and R 2 is (C 1 -C 6 ) haloalkoxy. In another embodiment, R 1 is halogen and R 2 is (C 1 -C 6 ) haloalkyl. In yet another embodiment, R 1 is halogen and R 2 is halogen.
  • B is unsubstituted heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S.
  • B is heteroaryl comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, substituted with one or more halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or (C 3 -C 8 ) cycloalkyl.
  • B is unsubstituted (C 6 -C 10 ) aryl.
  • B is (C 6 -C 10 ) aryl optionally substituted with (C 1 -C 6 ) alkyl, halogen, (C 1 -C 6 ) alkoxy, (C 1 -C 6 ) haloalkoxy, or (C 3 -C 8 ) cycloalkyl.
  • B is pyrimidinyl, furanyl, benzo[d]thiazolyl, 1-methyl-1H-benzo[d]imidazolyl, 1-methyl-1H-indolyl, benzo[d]isoxazolyl, 2,2-difluoro-1-methylindolin-3-onyl, or 7-fluoro-1-methyl-1H-benzo[d]imidazolyl, wherein each B is optionally substituted with one or more halogen, (C 1 -C 6 ) alkyl, (C 1 -C 6 ) alkoxy, or (C 1 -C 6 ) haloalkyl.
  • R 3 is (C 3 -C 8 ) cycloalkyl optionally substituted with halogen or (C 1 -C 6 ) alkyl. In another embodiment, R 3 is (C 3 -C 8 ) cycloalkyl optionally substituted with halogen. In another embodiment, R 3 is unsubstituted (C 3 -C 8 ) cycloalkyl.
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7 .
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 )
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 .
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 .
  • L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) hal
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalk
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkoxy
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl
  • L 1 is -(CH 2 ) p - and L 2 is a bond .
  • L 1 is -(CH 2 )p-
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 1
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) hal
  • L 1 is a -(CH 2 )p-, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4
  • L 1 is -(CH 2 ) p -, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 )
  • L 1 is -(CH 2 )p- and L 2 is a bond .
  • L 1 is -(CH 2 )p-
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 )p-
  • L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -, L 2 is a bond
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or (C 6 -C 10 ) aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is a -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 ) a
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 2 is halogen or (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is halogen or (C 1 -C 4 ) haloalkyl, and R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 )
  • L 1 is -(CH 2 )p-, L 2 is a bond and A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , and B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , and H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 ) alkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, and R 2 is halogen or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is halogen or (C 1 -C 4 ) haloalkyl, and R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 ) alkyl.
  • L 1 is -(CH 2 )p-, L 2 is a bond, and A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , and B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , and R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, and R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, and R 3 is (C 1 -C 4 ) alkyl or (C
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, and R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 )p-, L 2 is a bond, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, and R 3 is (C 1 -C 4 ) alkyl or (C 3 ) alky
  • L 1 is -(CH 2 )p-
  • L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 )p-
  • L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C
  • L 1 is -(CH 2 )p-, L 2 is a bond
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7 .
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is H, halogen,
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is hal
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 .
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 .
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , and H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 ) alkyl.
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 .
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 .
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -)
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4
  • L 1 is -(CH 2 ) p - and L 2 is -S(O) 2 -.
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , H, halogen, or (C 1 -C 4 ) haloalkyl, R 2 is H, halogen, or (C 3
  • L 1 is a -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl, (C 6 -C 10 ) aryl, or heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, wherein the cycloalkyl, aryl, or heterocycloalkyl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C
  • L 1 is -(CH 2 ) p - and L 2 is ⁇ S(O) 2 -.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is a -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl or (C 6 -C 10 ) aryl wherein the cycloalkyl or aryl are optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , and H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 ) alkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 ) haloalkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 3 -C 8 ) cycloalkyl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, or (C 1 -C 4 ) haloalkyl
  • R 2 is halogen or (C 1 -C 4 ) haloalkyl
  • R 3 is (C 3 -C 7 ) cycloalkyl optionally substituted with one or more substituents each independently selected from the group consisting of halogen or (C 1 -C 4 ) alkyl.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -, L 2 is ⁇ S(O) 2 -, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , and R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 3 is (C 1 -C 4
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 ) p -, L2 is ⁇ S(O) 2 -, A is (C 6 -C 10 ) aryl optionally substituted with one or more R 7 , B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 , R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy, and R 3 is (C 1 -C 4 )
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7 .
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5 .
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy.
  • L 1 is -(CH 2 ) p -
  • L 2 is -S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 )
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 )
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) hal
  • L 1 is -(CH 2 ) p -
  • L 2 is ⁇ S(O) 2 -
  • A is heterocycloalkyl wherein the heterocycloalkyl comprises one or two 5- to 7-membered rings and 1-4 heteroatoms selected from the group consisting of N, O and S, optionally substituted with one or more R 7
  • B is (C 6 -C 10 ) aryl or heteroaryl wherein the heteroaryl comprises one or two 5- or 6-member rings and 1-4 heteroatoms selected from the group consisting of N, O and S, and wherein the aryl or heteroaryl is optionally substituted with one or more R 5
  • R 1 is H, halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) haloalkyl, or (C 1 -C 4 ) haloalkoxy
  • R 2 is halogen, (C 1 -C 4 ) alkoxy, (C 1 -C 4 ) halo
  • Non-limiting illustrative compounds of the invention include:
  • the compound is selected from the group consisting of the group consisting of:
  • the compounds of Formula (I) are enantiomers. In some embodiments the compounds are the ( S )-enantiomer. In other embodiments the compounds are the (R)-enantiomer. In yet other embodiments, the compounds of Formula (I) may be (+) or (-) enantiomers.
  • the compounds of Formula (I) are diastereomers. It should be understood that all isomeric forms are included within the present invention, including mixtures thereof. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans configuration. All tautomeric forms are also intended to be included.
  • the compounds of the invention may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the invention as well as mixtures thereof, including racemic mixtures, form part of the present invention.
  • the present invention embraces all geometric and positional isomers. For example, if a compound of the invention incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
  • Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound.
  • the compounds may be in a racemic or enantiomerically pure form, or any other form in terms of stereochemistry.
  • the assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • converting e.g., hydrolyzing
  • some of the compounds of the invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention.
  • Enantiomers can also
  • the compounds of the invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the invention.
  • All stereoisomers for example, geometric isomers, optical isomers and the like
  • of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs
  • those which may exist due to asymmetric carbons on various substituents including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl).
  • the compounds of Formula I may form salts which are also within the scope of this invention.
  • Reference to a compound of the Formula herein is understood to include reference to salts thereof, unless otherwise indicated.
  • the present invention relates to compounds which are modulators of FXR.
  • the compounds of the present invention are activators (agonists) of FXR.
  • the invention is directed to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof.
  • the compounds of the present invention may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.
  • the compounds of Formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis ( T. W. Greene and P. G. M. Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999 ). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as the reaction conditions and order of their execution, shall be consistent with the preparation of compounds of Formula (I).
  • the present invention includes both possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and/or diastereomers as well.
  • a compound When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in the art. See, for example, " Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-lnterscience, 1994 ).
  • the compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and/or enzymatic processes.
  • the compounds of the present invention can be prepared in a number of ways well known to those skilled in the art of organic synthesis.
  • compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or variations thereof as appreciated by those skilled in the art. These methods include, but are not limited to, those described below.
  • Compounds of the present invention can be synthesized by following the steps outlined in General Schemes 1, 2, 3, and 4 which comprise different sequences of assembling intermediates. Starting materials are either commercially available or made by known procedures in the reported literature or as illustrated.
  • R 3b is an alkyl group
  • X is halogen (i.e., Cl, F, etc.) or another suitable leaving group (i.e., mesylate)
  • PG is a protecting group (i.e., tert -butyl carbonate (BOC)).
  • N-chlorosuccinimide in a solvent i.e., N,N -dimethylformamide (DMF)
  • a solvent i.e., dichloromethane
  • Acid 2f is treated with activating agent (i.e., 1,1'-Carbonyldiimidazole (CDI)) and then reacted with protected 3-hydroxyl-aza-bicycloheptane intermediate 2g1 or 2g2 in a solvent (i.e., DMF) optionally at elevated temperature to form ester 2h1 or 2h2.
  • activating agent i.e., 1,1'-Carbonyldiimidazole (CDI)
  • CDI 1,1'-Carbonyldiimidazole
  • acid 2f can be converted to an acid chloride using a chlorinating agent (i.e., thienyl chloride) in a solvent (i.e., DMF) and then reacted with protected 3-hydroxyl-aza-bicycloheptane intermediate 2g1 or 2g2 in the presence of DMAP and a base (i.e., triethylamine (Et 3 N)) and in a solvent (i.e., DMF) to form ester 2h1 or 2h2.
  • a chlorinating agent i.e., thienyl chloride
  • a solvent i.e., DMF
  • a base i.e., triethylamine (Et 3 N)
  • Et 3 N triethylamine
  • intermediate 2h1 or 2h2 i.e., when PG is an acid labile group, i.e., BOC
  • a strong acid i.e., trifluoroacetic acid (TFA)
  • a solvent i.e., dichloromethane (DCM)
  • 2i1 or 2i2 and 2j wherein R 4 in reagent 2j is optionally protected, are treated with a base in a solvent and optionally at elevated temperature to afford the desired product of Formula (I) when R 4 is unprotected, or advanced intermediate 2k1 or 2k2 when R 4 is protected.
  • Deprotection intermediate 2k1 or 2k2 provides the desired product of Formula (I) .
  • A, B, R 1 -R 4 and L 1 are defined as in Formula (I).
  • Alcohol 3a can be oxidized to the aldehyde 3e , which is further converted to the two carbon elongated ⁇ , ⁇ -unsaturated ester 3f via a standard Wittig reaction conditions (i.e., (Carboxymethyl)triphenylphosphonium bromide ethyl ester, a base (i.e., potassium tert-butoxide) and a solvent (i.e., THF)).
  • a standard Wittig reaction conditions i.e., (Carboxymethyl)triphenylphosphonium bromide ethyl ester, a base (i.e., potassium tert-butoxide) and a solvent (i.e., THF)
  • 3d or 3h and 3-hydroxyl-aza-bicycloheptane intermediate 2g1 are coupled using standard acylation conditions (i.e., treatment of 3h and 2g1 with DMAP and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in a solvent ( i.e., DCM)) to form the ester 3i .
  • Intermediate 3i can be converted to the desired product of Formula (I) as described above in steps 6 to 8 of General Scheme 1.
  • Compounds of Formula (I) can also be synthesized as described above in steps 1 to 8 of General Scheme 2 and steps 6 to 8 of General Scheme 1 from hydroxyl-aza-bicycloheptane intermediate 2g2 .
  • A, B, and R 1 -R 4 are defined as in Formula (I)
  • Nucleophilic addition of 2g1 to 3b in the presence of a base (i.e., sodium hydride (NaH)) and in a solvent (i.e., THF) provides 4a .
  • a base i.e., sodium hydride (NaH)
  • a solvent i.e., THF
  • Deprotection of intermediate 4a i.e., when PG is an acid labile group, i.e., BOC
  • a strong acid i.e., trifluoroacetic acid (TFA)
  • DCM dichloromethane
  • Another aspect of the invention is directed to a method of modulating FXR.
  • the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention is directed to a method of modulating FXR.
  • the method comprises administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the invention is directed to a method of activating FXR.
  • the method involves administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the invention is directed to a method of activating FXR.
  • the method involves administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the invention relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in which FXR plays a role.
  • the method comprises administering to a patient in need of a treatment for diseases or disorders in which FXR plays a role an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • Another aspect of the invention relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in which FXR plays a role.
  • the method comprises administering to a patient in need of a treatment for diseases or disorders in which FXR plays a role an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • Another aspect of the invention relates to a method of modulating FXR.
  • the method comprises administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • Another aspect of the invention relates to a method of modulating FXR.
  • the method comprises administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the present invention relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with the activation of FXR, the method comprising administering to a patient in need thereof an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • Another aspect of the present invention relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with the activation of FXR, the method comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating a liver disease.
  • the method comprises administering to a patient in need of a treatment for a liver disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating a liver disease.
  • the method comprises administering to a patient in need of a treatment for a liver disease an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating an intestinal disease.
  • the method comprises administering to a patient in need of a treatment for an intestinal disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating an intestinal disease.
  • the method comprises administering to a patient in need of a treatment for an intestinal disease an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating a kidney disease.
  • the method comprises administering to a patient in need of a treatment for a kidney disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating a kidney disease.
  • the method comprises administering to a patient in need of a treatment for a kidney disease an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating an autoimmune disease.
  • the method comprises administering to a patient in need of a treatment for an autoimmune disease an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating an autoimmune disease.
  • the method comprises administering to a patient in need of a treatment for an autoimmune disease an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating cancer.
  • the method comprises administering to a patient in need of a treatment for cancer an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the present invention relates to a method of treating, preventing, inhibiting, or eliminating cancer.
  • the method comprises administering to a patient in need of a treatment for cancer an effective amount of a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of a disease or disorder in which FXR plays a role.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of a disease or disorder in which FXR plays a role.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of a liver disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of a disease associated with activating FXR.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of a liver disease.
  • the present invention relates to a compound of Formula (I) or (Ia), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of an intestinal disease.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of an intestinal disease.
  • the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of a kidney disease.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of a kidney disease.
  • the present invention relates to a compound of Formula (I) or (Ia), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of an autoimmune disorder.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of an autoimmune disorder.
  • the present invention relates to a compound of Formula (I) or (Ia), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition, or elimination of cancer.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the treatment, prevention, inhibition, or elimination of cancer.
  • Another aspect of the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder in which FXR plays a role.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder or cancer.
  • Another aspect of the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder in which FXR plays a role.
  • the disease or disorder is a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder or cancer.
  • the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a liver disease.
  • the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a liver disease.
  • the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating an intestinal disease.
  • the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating an intestinal disease.
  • the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a kidney disease.
  • the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a kidney disease.
  • the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating an autoimmune disease.
  • the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating an autoimmune disease.
  • the present invention relates to the use of a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a cancer.
  • the present invention relates to the use of a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a cancer.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease associated with activating FXR.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating a disease associated with activating FXR.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a disease in which FXR plays a role.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating a disease in which FXR plays a role.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a liver disease.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating a liver disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating an intestinal disease.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating an intestinal disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a kidney disease.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating a kidney disease.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating an autoimmune disorder.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating an autoimmune disorder.
  • Another aspect of the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating cancer.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier, for use in the manufacture of a medicament for treating cancer.
  • the present invention relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a liver disease.
  • the present invention relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of an intestinal disease.
  • the present invention relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a kidney disease.
  • the present invention relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of an autoimmune disorder.
  • the present invention relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition or elimination of a cancer.
  • the present invention also relates to the use of an activator of FXR for the preparation of a medicament used in the treatment, prevention, inhibition, or elimination of a disease or condition in which FXR plays a role, wherein the medicament comprises a compound of Formula (I).
  • the present invention relates to a method for the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or condition mediated by FXR, wherein the medicament comprises a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
  • the disease or condition is selected from the group consisting of liver disease, intestinal disease, kidney disease, an autoimmune disorder, or cancer.
  • the disease can be any disease including, but not limited to, Alagille syndrome (ALGS), atherosclerosis, biliary atresia, Byler disease, gallstone disease, hyperlipidemia, hepatocellular carcinoma, hepatocellular adenoma, cholangiocarcinoma, colorectal cancer, colorectal adenoma, ileal adenoma, renal cancer, oesophageal cancer, obesity, type-2 diabetes mellitus, and gastric cancer.
  • AGS Alagille syndrome
  • atherosclerosis atherosclerosis
  • biliary atresia Byler disease
  • gallstone disease gallstone disease
  • hyperlipidemia hepatocellular carcinoma
  • hepatocellular adenoma cholangiocarcinoma
  • colorectal cancer colorectal adenoma
  • the liver disease can be any liver diseases, including, but not limited to, primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, intra- and extra-cholestasis, biliary atresia, portal vein hypertension (PAH), spontaneous bacterial peritonitis (SBP), acute decompensation liver failure, hepatorenal syndrome and hepatic encephalopathy.
  • PBC primary biliary cirrhosis
  • PSC primary sclerosing cholangitis
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • alcoholic liver disease intra- and extra-cholestasis
  • biliary atresia portal vein hypertension
  • PAH portal vein hypertension
  • SBP spontaneous bacterial peritonitis
  • the intestinal disease can be any intestinal disease, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, proctitis, pouchitis, Celiac's disease and bile acid diarrhea.
  • the disease is an intestinal permeability disease, disorder or condition mediated by tight junction dysfunction.
  • the disease, disorder or condition is gastric ulcers, infectious diarrhea, irritable bowel syndrome, functional GI diseases (IBS, IBS-C, IBS-D, IBS-M, post infectious IBS), inflammatory bowel disease (CD, UC), Celiac's, cancer (colorectal), Leaky Gut Syndrome, cystic fibrosis GI manifestations, multi-organ failure, microscopic colitis or necrotizing enterocolitis.
  • compounds of the invention are used to treat one of the following disease, disorder or condition: allergy e.g. atopy, food allergy; infections e.g. respiratory infections; acute inflammation e.g. sepsis, SIRS, MOF); chronic inflammation e.g. arthritis; obesity-induced metabolic diseases e.g. NASH, diabetes, T1D/T2D, CVD; kidney disease e.g. chronic kidney disease, diabetic kidney disease; heart disease e.g. heart failure, congestive heart failure; liver disease e.g. cirrhosis, NASH, NAFLD, steatosis, PSC, PBC, portal hypertension; autoimmune disease e.g.
  • type 1 diabetes, celiac disease, multiple sclerosis, IBD, ankylosing spondylitis, RA, lupus, alopecia areata, rheumatoid arthritis, polymyalgia rheumatica, multiple sclerosis, fibromyalgia, chronic fatigue syndrome, Sjogren's syndrome, vitiligo, thyroiditis, vasculitis, Crohn's disease, ulcerative colitis, urticaria (hives) and Raynaud's syndrome; neurological e.g. schizophrenia, autism spectrum disorders, multiple sclerosis, hepatic encephlopathy; and chronic alcoholism
  • the kidney disease can be any kidney disease, including, but not limited to, fibrotic renal disease and diabetic nephrophathy.
  • the autoimmune disorder can be any autoimmune disorder, including, but not limited to, inflammatory bowel disease, autoimmune hepatitis, autoimmune liver disease (primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)), and multiple sclerosis.
  • inflammatory bowel disease autoimmune hepatitis
  • autoimmune liver disease primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC)
  • PBC primary biliary cirrhosis
  • PSC primary sclerosing cholangitis
  • the cancer can be any cancer including, but not limited to, a cancer is selected from the group consisting of hepatocellular carcinoma, hepatocellular adenoma, cholangiocarcinoma, colorectal cancer, colorectal adenoma, ileal adenoma, renal cancer, oesophageal cancer, or gastric cancer.
  • the present invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, of the present invention and a pharmaceutically acceptable carrier used for the treatment of diseases including, but not limited to liver diseases, intestinal diseases, kidney diseases, autoimmune disorders or cancer.
  • compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
  • a disease or disorder in which FXR plays a role including a liver disease, an intestinal disease, a kidney disease or an autoimmune disorder comprising administering to a patient suffering from at least one of said diseases or disorder a compound of Formula (I).
  • One therapeutic use of the compounds or compositions of the present invention which activate FXR is to provide treatment to patients or subjects suffering from a liver disease, an intestinal disease, a kidney disease, an autoimmune disorder, or cancer.
  • the disclosed compounds of the invention can be administered in effective amounts to treat or prevent a disorder and/or prevent the development thereof in subjects.
  • Administration of the disclosed compounds can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
  • compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
  • injectables tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices.
  • they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
  • Illustrative pharmaceutical compositions are tablets and gelatin capsules comprising a Compound of the Invention and a pharmaceutically acceptable carrier, such as a) a diluent, e.g., purified water, triglyceride oils, such as hydrogenated or partially hydrogenated vegetable oil, or mixtures thereof, com oil, olive oil, sunflower oil, safflower oil, fish oils, such as EPA or DHA, or their esters or triglycerides or mixtures thereof, omega-3 fatty acids or derivatives thereof, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, sodium, saccharin, glucose and/or glycine; b) a lubricant, e.g., silica, talcum, stearic acid, its magnesium or calcium salt, sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and/or polyethylene glycol; for tablets also
  • Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc.
  • the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension.
  • a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like.
  • Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
  • the disclosed compounds can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
  • the disclosed compounds can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, containing cholesterol, stearylamine or phosphatidylcholines.
  • a film of lipid components is hydrated with an aqueous solution of drug to a form lipid layer encapsulating the drug, as described in U.S. Pat. No. 5,262,564 which is hereby incorporated by reference in its entirety.
  • Disclosed compounds can also be delivered by the use of monoclonal antibodies as individual carriers to which the disclosed compounds are coupled.
  • the disclosed compounds can also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspanamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
  • Disclosed compounds can be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
  • a polymer e.g., a polycarboxylic acid polymer, or a polyacrylate.
  • Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
  • compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.
  • the pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant.
  • compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1% to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
  • the dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed.
  • a physician or veterinarian of ordinary skill in the art can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
  • Effective dosage amounts of the disclosed compounds when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition.
  • Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses.
  • the compositions are in the form of a tablet that can be scored.
  • Example 1 Intermediate. Benzyl (1S,4S,5R)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (C-1) and (1S,4R,6S)-Benzyl 6-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate (C-2)
  • Example 2 Intermediate. Benzyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (C-4) and Benzyl (1R,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (C-5)
  • Example 3 Intermediates. Benzyl (1R,4R,5S)-5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (C-4) and Benzyl (1R,4S,6R)-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate (C-5)
  • the resulting white suspension was filtered through a Celite pad and the pad was washed with anhydrous THF (250.0 mL).
  • the clear filtrate was cooled to 0 °C and then treated with trimethylamine (12.8 mL, 91.6 mmol) and CbzCl (10.3mL, 68.7 mmol).
  • the reaction mixture was slowly warmed to room temperature and stirred for 48 hours.
  • the white precipitate was filtered and the resulting clear filtrate solution was concentrated to dryness.
  • the mixture was stirred at 0 °C for 2 h, and then at 40 °C overnight
  • the reaction mixture was cooled to 0 °C, and a second batch of NaSCN (12.2 g, 150.49 mmol, 5.0 equiv.) was added, followed by the dropwise addition of a solution of bromine (9.6 g, 60.07 mmol, 2.0 equiv.) in AcOH (50 mL) over 1 hr.
  • the reaction mixture was stirred at 0 °C for 2 h, and then at 40 °C for 3 days.
  • the resulting mixture was diluted with 200 mL of water and the pH value of the aqueous solution was adjusted to 9 with sodium hydroxide.
  • methyl 4-amino-3-methylbenzoate A-6a (10.0 g, 60.54 mmol, 1.0 equiv.), AcOH (200 mL), and NaSCN (19.6 g, 4.0 equiv.) followed by the dropwise addition of a solution of bromine (9.7 g, 60.70 mmol, 1.0 equiv.) in AcOH (100 mL) at 0 °C.
  • the resulting mixture was stirred at 30 °C for 16 h and then quenched by the addition of 500 mL of ice water.
  • the pH value of the aqueous solution was adjusted to 9 using sodium hydroxide.
  • 6-bromo-1H-indole-3-carboxylic acid A-8a (5 g, 20.83 mmol, 1.0 equiv.), N,N-dimethylformamide (150 mL), MeI (5.9 g), and sodium hydride (3.5 g, 145.83 mmol, 7.0 equiv.).
  • the resulting mixture was stirred at 10-25 °C for 1 h, and then diluted with 1500 mL of H 2 O.
  • the aqueous mixture was extracted with ethyl acetate (200 mL ⁇ 3) and the combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo.
  • N -[(2,6-dichlorophenyl) methylidene] hydroxylamine 1b 60 g, 315.74 mmol, 1.0 equiv.
  • N , N -dimethylformamide 250 mL
  • N-chlorosuccinimide NCS, 42.5 g, 318.28 mmol, 1.0 equiv.
  • Step 8 Methyl 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]carbonyloxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylate (1k)
  • N-[[2-(trifluoromethyl) phenyl]methylidene]-hydroxylamine 9b (10 g, 52.87 mmol, 1.0 equiv.), N,N-dimethylformamide (50 mL), and NCS (7.5 g, 56.17 mmol, 1.06 equiv.).
  • the resulting mixture was stirred at 10-25 °C for 2 h, and then diluted with 200 mL of H 2 O.
  • N-hydroxy-2-(trifluoromethyl)benzene-1-carbonimidoyl chloride 9c (11.5 g, 51.44 mmol, 1.0 equiv.), ethyl 3-cyclopropyl-3-oxopropanoate 1d (12 g, 76.83 mmol, 1.49 equiv.), and TEA (50 mL) and the resulting mixture was stirred at 10-25 °C overnight.
  • the reaction mixture was diluted with 200 mL of H 2 O and the pH of the aqueous solution was adjusted to 5-6 using a hydrogen chloride (aq.).
  • Step 8 Methyl 2-[(1S,4S,5R)-5-([5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]carbonyloxy)-2-azabicyclo[2.2.1]heptan-2-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylate (9i)
  • the crude product was purified by silica gel column chromatography eluting with PE:EA (0%-5%) to provide(75%) of ethyl 3-(1-fluorocyclopropyl)-3-oxopropanoate 10d as a yellow oil (volatile product, removal of solvents on rotavap should be done at low temperature).
  • Step 8 Methyl 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]carbonyloxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylate (10j)
  • N-[bicyclo[2.2.2]octan-1-ylmethylidene]-hydroxylamine 11g (2.3 g, 15.01 mmol, 1.0 equiv.) and N,N-dimethylformamide (20 mL).
  • NCS (3.1 g, 23.13 mmol, 1.50 equiv.).
  • the reaction mixture was stirred for 2 h at room temperature and then 300 mL of ethyl acetate was added.
  • Step 8 3-[bicyclo[2.2.2]octan-1-yl]-5-cyclopropyl-1,2-oxazole-4-carboxylic acid (11k)
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column 5 ⁇ m, 19 mm ⁇ 250 mm; mobile phase, water (0.05%TFA ) and ACN (82.0% ACN to 90.0% over 8 min); Detector, UV 254 nm, to provide19.7 mg (25%) of 2-[(1S,4S,5R)-5-[(3-[bicyclo[2.2.2]octan-1-yl]-5-cyclopropyl-1,2-oxazol-4-yl)carbonyloxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 1-11 was obtained as an off-white solid.
  • the aqueous mixture was extracted with ethyl acetate (200 mL x2), and the combined organic extracts were washed with brine (200 mL ⁇ 2) and concentrated.
  • Step 5 Methyl 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylate (12e)
  • Step 6 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid (I-12)
  • reaction was then quenched by the addition of 50 mL of H 2 O and the pH value of the solution was adjusted to 3-4 using aqueous hydrogen chloride (1M).
  • aqueous hydrogen chloride (1M) was extracted with ethyl acetate (30 mL ⁇ 3) and the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column, 19 mm ⁇ 250 mm; mobile phase, Water (0.05%TFA ) and ACN (56% ACN to 78% over 8 min); Detector, UV 254 nm, to provide 50.5 mg (13%) of 2-[(1S,4S,SR)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 1-12 as an off-white solid.
  • Step 3 Benzyl (1S,4S,5R)-5-([5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (19c)
  • the resulting mixture was diluted with 30 mL of ethyl acetate, and 30 mL of water/ice was then added.
  • the aqueous mixture was extracted with ethyl acetate (30 mL ⁇ 2) and the combined organic extracts were washed with brine (60 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the resulting mixture was stirred at 50 °C for 2 h. Upon cooling to room temperature, 5 mL of H 2 O was added and the pH value of the solution was adjusted to 2 using a aqueous hydrogen chloride (1M). The aqueous mixture was extracted with 50 mL of ethyl acetate and the organic extract was washed with brine (100 mL ⁇ 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column, 19 mm ⁇ 250 mm; mobile phase, Water (0.05%TFA ) and ACN (63.0% to 78.0% over 8 min); Detector, UV 254 nm, to provide 80.3 mg (51%) of 2-[(1S,4S,5R)-5-([5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy)-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 1-19 as a colorless solid.
  • the resulting mixture was stirred at room temperature for 2 h and then diluted with 10 mL of H 2 O.
  • the pH value of the solution was adjusted to 2 using aqueous HCl (1M).
  • the aqueous mixture was extracted with ethyl acetate (50 mL ⁇ 2) and the combined organic extracts were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge BEH130 Prep C18 OBD Column, 150 mm ⁇ 5 um 13 nm; mobile phase, Water (0.05%TFA ) and ACN (70.0% to 85.0% over 8 min); Detector, UV 254 nm, to provide 33.8 mg (21%) of 2-[(1S,4S,5R)-5-([5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy)-2-azabicyclo[2.2.1]heptan-2-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylic acid 1-20 as a colorless solid.
  • Step 6 Benzyl (1S,4S,5R)-5-((3-cyclohexyl-5-cyclopropylisoxazol-4-yl)methoxy)-2-azabicyclo[2.2.1]heptane-2-carboxylate (21g).
  • the mixture was diluted with of H 2 O.
  • the aqueous mixture was extracted with of ethyl acetate (50 mL ⁇ 3); the combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the pH value of the solution was adjusted to 3.0 using a 1M hydrogen chloride solution.
  • the aqueous mixture was extracted with dichloromethane (50 mL ⁇ 3); the combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column, 19 mm ⁇ 250 mm; mobile phase, Water (0.05%TFA ) and ACN (67.0% ACN up to 83.0% in 8 min); Detector, UV 254nm.
  • N-(tetrahydropyran-4-ylmethylidene)-hydroxylamine 23b 200 mg, 1.55 mmol, 1.0 equiv.
  • N,N-dimethylformamide 2 mL
  • NCS 200 mg, 1.50 mmol, 1.0 equiv.
  • N-hydroxyox-4-carbonimidoyl chloride 23c (2.4 g, 14.67 mmol, 1.0 equiv.) in tetrahydrofuran (20 mL) was then added dropwise at 0°C and the resulting mixture was stirred at room temperature for 3 h. The mixture was diluted with 100 mL of ethyl acetate and the organic extract was washed with brine (100 mL) and concentrated under reduced pressure. The resulting solid was dried in an oven under reduced pressure to afford 3 g (77%) of ethyl 5-cyclopropyl-3-(oxan-4-yl)-1,2-oxazole-4-carboxylate 23d as a crude yellow oil. The crude product was carried onto the next step without further purification.
  • the resulting mixture was stirred at room temperature for 1h, and then quenched by the addition of water/ice.
  • the aqueous mixture was diluted with 20 mL of ethyl acetate, and further extracted with ethyl acetate (50 mL ⁇ 2).
  • the combined organic extracts were washed with brine (100 mL x2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the resulting mixture was stirred at 2 5°C overnight, and then diluted with 2 mL of H 2 O.
  • the pH of the aqueous mixture was adjusted to 2 using aqueous HCl (1M).
  • the aqueous mixture was extracted with ethyl acetate (50 mL) and the organic extract was washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column, 19 mm ⁇ 250 mm; mobile phase, Water (0.05%TFA ) and ACN (50.0% 70.0% over 8 min); Detector, UV 254 nm, to provide 36.6 mg (54%) of 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(oxan-4-yl)-1,2-oxazol-4yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylic acid 1-23 as a colorless solid.
  • the resulting mixture was stirred at room temperature for 2 h and then quenched by the addition of 5 mL of water/ice.
  • the aqueous mixture was extracted with 200 mL of ethyl acetate and the organic extract was washed with brine (30 mL x4), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure.
  • the crude product was purified by Prep-HPLC using the following conditions: Column, XBridge C18 OBD Prep Column 5 ⁇ m, 19 mm ⁇ 250 mm; mobile phase, water (0.05%TFA ) and ACN (60.0% to 80.0% over 8 min); Detector, UV 254 nm, to provide 9.5 mg (24%) of 2-[(1S,4S,5R)-5-[[3-(2,6-dichlorophenyl)-5-(1-fluorocyclopropyl)-1,2-oxazol-4-yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid 1-24 was obtained as an off-white solid.
  • Step 2 2-[(1S,4S,5R)-5-[[5-(2,6-dichlorophenyl)-3-(1-fluorocyclopropyl)-2H-pyrrol-4-yl]methoxy]-2-azabicyclo [2.2.1]heptan-2-yl]-4-(trifluoromethoxy)-1,3-benzothiazole-6-carboxylic acid (I-25)
  • reaction was then quenched by the addition of 100 mL of ice/salt and the aqueous mixture was extracted with ethyl acetate (100 mL ⁇ 3). The combined organic extracts were washed with brine (100 mL ⁇ 3), dried over anhydrous sodium sulfate, filtered, and concentrated.
  • Step 4 2-[(1S,4S,5R)-5-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-azabicyclo[2.2.1]heptan-2-yl]-6-(2H-1,2,3,4-tetrazol-5-yl)-4-(trifluoromethoxy)-1,3-benzothiazole (I-27)
  • Example 36 N-(cyclopropanesulfonyl)-2-[(1S,4S,5R)-5- ⁇ [5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy)-2-azabicyclo[2.2.1]heptan-2-yl]-4-fluoro-1,3-benzothiazole-6-carboxamide (1-30)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
EP21181833.1A 2016-08-23 2017-08-23 Verfahren zur herstellung von hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen Pending EP3954684A1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662378625P 2016-08-23 2016-08-23
US201762532983P 2017-07-14 2017-07-14
PCT/US2017/048281 WO2018039386A1 (en) 2016-08-23 2017-08-23 Hormone receptor modulators for treating metabolic conditions and disorders
EP17768538.5A EP3504205B1 (de) 2016-08-23 2017-08-23 Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP17768538.5A Division EP3504205B1 (de) 2016-08-23 2017-08-23 Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen
EP17768538.5A Division-Into EP3504205B1 (de) 2016-08-23 2017-08-23 Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen

Publications (1)

Publication Number Publication Date
EP3954684A1 true EP3954684A1 (de) 2022-02-16

Family

ID=59895359

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21181833.1A Pending EP3954684A1 (de) 2016-08-23 2017-08-23 Verfahren zur herstellung von hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen
EP17768538.5A Active EP3504205B1 (de) 2016-08-23 2017-08-23 Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP17768538.5A Active EP3504205B1 (de) 2016-08-23 2017-08-23 Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen

Country Status (6)

Country Link
US (3) US10793568B2 (de)
EP (2) EP3954684A1 (de)
JP (3) JP7093341B2 (de)
CN (2) CN110177783B (de)
MA (2) MA46052A (de)
WO (1) WO2018039386A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (de) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen
NZ735126A (en) 2015-03-31 2022-10-28 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3730487B1 (de) 2016-06-13 2022-04-27 Gilead Sciences, Inc. Azetidin abkömmlinge als fxr(nr1h4)-modulierende verbindungen
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US11091482B2 (en) 2016-08-23 2021-08-17 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
MA46052A (fr) * 2016-08-23 2021-03-17 Ardelyx Inc Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
MX2019003790A (es) 2016-10-04 2019-09-26 Enanta Pharm Inc Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
KR20190126920A (ko) 2017-03-28 2019-11-12 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
AU2018298253B2 (en) * 2017-07-06 2020-11-19 Xuanzhu Biopharmaceutical Co., Ltd. FXR receptor agonist
WO2019055808A1 (en) * 2017-09-14 2019-03-21 Ardelyx, Inc. HORMONE RECEPTOR MODULATORS FOR THE TREATMENT OF MUTAGENIC AND FIBROTIC METABOLIC CONDITIONS AND DISORDERS
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2020001304A1 (zh) * 2018-06-26 2020-01-02 轩竹（海南）医药科技有限公司 Fxr受体激动剂
CN108774194A (zh) * 2018-07-23 2018-11-09 南京纽邦生物科技有限公司 一种2-[(2-苯并噻唑甲基)硫基]-6-乙氧基苯并噻唑及其中间体的制备方法
BR112021002050A2 (pt) * 2018-08-08 2021-05-04 Inorbit Therapeutics Ab composto, composição farmacêutica, e, métodos para modular e ativar um receptor farsenoide x (fxr) e para tratar e/ou prevenir uma doença ou transtorno
EA202191566A1 (ru) 2019-01-15 2021-11-01 Джилид Сайенсиз, Инк. Соединения, модулирующие fxr (nr1h4)
CA3129949C (en) 2019-02-19 2024-04-30 Gilead Sciences, Inc. Solid forms of fxr agonists
JP7398605B2 (ja) * 2019-04-19 2023-12-15 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ Ｆｘｒ小分子アゴニストとその調製方法および用途
CN111825667B (zh) * 2019-04-19 2023-07-25 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
CN111892591A (zh) * 2019-05-06 2020-11-06 南京科技职业学院 一种维奈托克关键中间体的合成方法
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CA3159261A1 (en) * 2019-11-29 2021-06-03 Sunshine Lake Pharma Co., Ltd. Amorphous form of nitrogen-containing tricyclic compound and use thereof
CN111303034A (zh) * 2020-03-18 2020-06-19 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸的制备方法
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
CN111943848B (zh) * 2020-08-19 2023-05-05 苏州旺山旺水生物医药有限公司 一种elexacaftor中间体的制备方法及其应用
PE20240118A1 (es) * 2020-12-30 2024-01-22 Terns Pharmaceuticals Inc Compuestos y metodos para modular elfxr
WO2022179636A1 (zh) * 2021-02-27 2022-09-01 轩竹生物科技股份有限公司 Fxr受体激动剂的晶型
CN113024552B (zh) * 2021-03-26 2022-08-05 厦门市博瑞来医药科技有限公司 一类新型非甾体fxr激动剂的合成及其应用
CN114773162A (zh) * 2022-03-27 2022-07-22 江苏壹药新材料有限公司 一种4-(3-羟基丙烯基)-2-三氟甲基苯酚的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr
WO2016127924A1 (en) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Tricyclic compounds and uses thereof in medicine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
JP2014500318A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
CN103391937A (zh) 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
WO2016097933A1 (en) 2014-12-18 2016-06-23 Novartis Ag Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
MA46052A (fr) * 2016-08-23 2021-03-17 Ardelyx Inc Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
AU2018298253B2 (en) * 2017-07-06 2020-11-19 Xuanzhu Biopharmaceutical Co., Ltd. FXR receptor agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012087519A1 (en) * 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating fxr
WO2016127924A1 (en) * 2015-02-13 2016-08-18 Sunshine Lake Pharma Co., Ltd. Tricyclic compounds and uses thereof in medicine

Also Published As

Publication number Publication date
WO2018039386A1 (en) 2018-03-01
MA46052A (fr) 2021-03-17
CN110177783A (zh) 2019-08-27
MA55632A (fr) 2022-02-16
US10793568B2 (en) 2020-10-06
CN110177783B (zh) 2023-06-06
JP2024038260A (ja) 2024-03-19
EP3504205B1 (de) 2021-08-04
US20210017177A1 (en) 2021-01-21
CN116854681A (zh) 2023-10-10
EP3504205A1 (de) 2019-07-03
JP2019531271A (ja) 2019-10-31
JP2022050527A (ja) 2022-03-30
US20190233420A1 (en) 2019-08-01
US20230139597A1 (en) 2023-05-04
JP7093341B2 (ja) 2022-06-29

Similar Documents

Publication Publication Date Title
EP3504205B1 (de) Hormon-rezeptor-modulatoren zur behandlung von metabolischen bedingungen und störungen
JP6845897B2 (ja) Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
US11820746B2 (en) Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides
US10370343B2 (en) [6,6] Fused bicyclic HDAC8 inhibitors
TW202304878A (zh) 含有具有縮合環之glp-1受體促效劑的醫藥組合物
EP3305789A1 (de) Stickstoffhaltiges trizyklisches derivat mit hiv-replikationshemmender wirkung
JP2021534240A (ja) トランスグルタミナーゼ２（ｔｇ２）阻害剤
EP3681881B1 (de) Hormonrezeptormodulatoren zur behandlung metabolischer mutagener und fibrotischer erkrankungen und störungen
CN117377666A (zh) 含有具有稠环的glp-1受体激动剂的药物组合物
WO2024006781A1 (en) Estrogen receptor alpha degraders and use thereof
CN117597336A (zh) 作为造血祖细胞激酶1(hpk1)抑制剂的卤素取代的氨基氮杂-杂芳基化合物
TW202417425A (zh) 雌激素受體α降解劑及其使用方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3504205

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220816

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230830